Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients
- PMID:15214887
- PMCID:PMC7129386
- DOI:10.1111/j.1469-0691.2004.00956.x
Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients
Abstract
Treatment of severe acute respiratory syndrome (SARS) is experimental, and the effectiveness of ribavirin-steroid therapy is unclear. Forty SARS patients with progressive disease after ribavirin treatment and 1.5 g of pulsed methylprednisolone were given either convalescent plasma (n = 19) or further pulsed methylprednisolone (n = 21) in a retrospective non-randomised study. Good clinical outcome was defined as discharge by day 22 following the onset of symptoms. Convalescent plasma was obtained from recovered patients after informed consent. Patients in the plasma group had a shorter hospital stay (p 0.001) and lower mortality (p 0.049) than the comparator group. No immediate adverse effects were observed following plasma infusion.
Similar articles
-
High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome.Am J Respir Crit Care Med. 2003 Dec 15;168(12):1449-56. doi: 10.1164/rccm.200306-766OC. Epub 2003 Aug 28. Am J Respir Crit Care Med. 2003. PMID:12947028
-
Outcome of coronavirus-associated severe acute respiratory syndrome using a standard treatment protocol.Respirology. 2004 Jun;9(2):173-83. doi: 10.1111/j.1440-1843.2004.00588.x. Respirology. 2004. PMID:15182266 Free PMC article.
-
SARS: pharmacotherapy.Respirology. 2003 Nov;8 Suppl:S25-30. doi: 10.1046/j.1440-1843.2003.00525.x. Respirology. 2003. PMID:15018130 Review.
-
Use of convalescent plasma therapy in SARS patients in Hong Kong.Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6. doi: 10.1007/s10096-004-1271-9. Eur J Clin Microbiol Infect Dis. 2005. PMID:15616839 Free PMC article.
-
[Experience with empirical treatment of severe acute respiratory syndrome due to coronavirus, genotype IV].Antibiot Khimioter. 2011;56(7-8):42-6. Antibiot Khimioter. 2011. PMID:22359870 Review. Russian.
Cited by192articles
-
Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines.Mol Biomed. 2020 Dec 3;1(1):16. doi: 10.1186/s43556-020-00017-w. Mol Biomed. 2020. PMID:35006461 Review.
-
Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19.Mol Biomed. 2021 Jan 20;2(1):1. doi: 10.1186/s43556-020-00015-y. Mol Biomed. 2021. PMID:35006419 Review.
-
Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of the potentialities and risks.Int J Surg. 2022 Jan;97:106204. doi: 10.1016/j.ijsu.2021.106204. Epub 2021 Dec 30. Int J Surg. 2022. PMID:34974199 Free PMC article. Review.
-
Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment.Front Pharmacol. 2021 Nov 22;12:732403. doi: 10.3389/fphar.2021.732403. eCollection 2021. Front Pharmacol. 2021. PMID:34880750 Free PMC article. Review.
-
Convalescent Plasma-A Light at the End of the Tunnel: A Systematic Review and Meta-analysis of Randomized Controlled Trials.印度J暴击治疗。2021年11月,25(11):1292 - 1300。doi: 10.5005/jp-journals-10071-24023. Indian J Crit Care Med. 2021. PMID:34866829 Free PMC article.
References
-
- Lee N, Hui DS, Wu A et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 1986–1994. -PubMed
-
- Ksiazek TG, Erdman D, Goldsmith CS et al. A novel coronavirus associated severe acute respiratory syndrome. N Engl J Med 2003; 348: 1953–1966. -PubMed
-
- Drosten C, Gunther S, Preiser W et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1967–1976. -PubMed
-
- 中心说ease Control and Prevention. Update: severe acute respiratory syndrome. MMWR 2003; 52: 388–390. -PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous